logo
SEGA SAMMY Nears Completion of Regulatory Approvals to Acquire GAN

SEGA SAMMY Nears Completion of Regulatory Approvals to Acquire GAN

Business Wire19-05-2025

LAS VEGAS--(BUSINESS WIRE)--GAN Limited (the 'Company' or 'GAN') (NASDAQ: GAN), a leading North American B2B technology provider of real money internet gaming solutions and a leading International B2C operator of Internet sports betting, today announced that SEGA SAMMY HOLDINGS INC. ('SEGA SAMMY HOLDINGS') through its affiliated entity SEGA SAMMY CREATION INC. ('SSC') is nearing completion of procurement of all gaming regulatory approvals necessary to complete its planned acquisition of GAN.
GAN and SSC are parties to an Agreement and Plan of Merger dated November 7, 2023 (the 'Merger Agreement') pursuant to which GAN would merge into and become a wholly owned subsidiary of SSC (the 'Merger').
The closing of the Merger is expected to occur on or about May 27, 2025. The closing remains subject to final gaming regulatory approvals and satisfaction of conditions to closing set out in the Merger Agreement. If the Merger is completed, each ordinary share of GAN issued and outstanding immediately prior to the effective time of the Merger will be cancelled and converted into the right to receive $1.97 in cash, without interest and less applicable withholding taxes. If the Merger is completed, GAN will cease to be a publicly traded company.
About GAN
GAN is a leading business-to-business supplier of internet gaming software-as-a-service solutions predominantly to the U.S. land-based casino industry. Coolbet, a division of GAN, is a market-leading operator of proprietary online sports betting technology with market leadership positions in select European and Latin American markets. GAN has developed a proprietary internet gaming enterprise software system, GameSTACK™, which it licenses to land-based casino operators as a turnkey technology solution for regulated real money internet gaming, encompassing internet gaming, internet sports gaming, and virtual Simulated Gaming. Additional information about GAN can be found online at www.GAN.com.
About SEGA SAMMY HOLDINGS
SEGA SAMMY HOLDINGS is the holding company of the SEGA SAMMY Group, a group of companies comprising the Entertainment Contents Business, which offers a diversity of fun through consumer and arcade game content, toys and animation; the Pachislot and Pachinko Machines Business, which conducts everything from development to sales of Pachinko/Pachislot machines; and the Gaming Business, which operates integrated resorts and develops casino gaming products and software.
SSC is a wholly-owned subsidiary of SEGA SAMMY HOLDINGS. SSC, together with its wholly-owned subsidiary SEGA SAMMY CREATION USA Inc., develop, manufacture and distribute land-based and online/social casino gaming products and software.
Forward-Looking Statements
This press release contains 'forward looking statements' regarding the closing of the merger and the expected timing thereof and other future related events. Such statements are based upon current estimates and expectations that are subject to risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Factors that could cause actual events to differ include, but are not limited to the failure to satisfy the closing conditions to the merger, and other risks detailed in GAN's filings with the SEC, including its proxy statement filed with the SEC on January 9, 2024. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GAN undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

How major US stock indexes fared Wednesday, 5/28/2025
How major US stock indexes fared Wednesday, 5/28/2025

San Francisco Chronicle​

time5 minutes ago

  • San Francisco Chronicle​

How major US stock indexes fared Wednesday, 5/28/2025

U.S. stocks closed lower a day after leaping back within a few good days' worth of gains from their all-time high. The S&P 500 fell 0.6% Wednesday after meandering between earlier gains and losses. The Dow Jones Industrial Average lost 0.6%, and the Nasdaq composite fell 0.5%. Abercrombie & Fitch soared after its profit and revenue beat analysts' expectations, while Macy's swung between gains and losses despite likewise also delivering better results than expected. The S&P 500 fell 32.99 points, or 0.6%, to 5,888.55. The Nasdaq composite fell 98.23 points, or 0.5%, to 19,100.94. The Russell 2000 index of smaller companies fell 22.60 points, or 1.1%, to 2,067.80. The S&P 500 is up 85.73 points, or 1.5%. The Dow is up 495.63 points, or 1.2%. The Nasdaq is up 363.73 points, or 1.9%. The Russell 2000 is up 27.95 points, or 1.4%. For the year: The S&P 500 is up 6.92 points, or 0.1%. The Dow is down 445.52 points, or 1%. The Nasdaq is down 209.86 points, or 1.1%. The Russell 2000 is down 162.36 points, or 7.3%.

Chelsea makes history after scintillating comeback in Conference League final
Chelsea makes history after scintillating comeback in Conference League final

CNN

time14 minutes ago

  • CNN

Chelsea makes history after scintillating comeback in Conference League final

Chelsea won the Conference League after beating Real Betis 4-1 in Wednesday's final in Wroclaw, Poland. The Blues got off to a sluggish start and were second best throughout the opening 45 minutes, but a rousing second half turned things around for the English side. After trailing 1-0 at the break, Chelsea grew into the game and blew its opponents away with four quickfire second half goals. Chelsea is now the first team to complete the full set of European trophies. The Blues add the Conference League to its Champions League and Europa League wins in previous years. Real Betis took a shock early lead when Abde Ezzalzouli drilled home a low strike past Chelsea goalkeeper Filip Jörgensen inside the opening 10 minutes. The goal, however, was largely orchestrated by Real Betis' captain, Isco. The 33-year-old veteran is instrumental in how his team operate and the side's conductor was responsible for carving out the opportunity for the opening goal. The diminutive playmaker drove at the heart of the Chelsea defense – attracting the attention of three defenders – before sliding a ball into the path of Ezzalzouli. The Moroccan winger kept his composure and fired home to give his side the advantage in an otherwise scrappy affair. Los Verdiblancos went into the halftime break 1-0 up and knew it was just 45 minutes from sealing a famous win. Chelsea, and in particular Cole Palmer, had other ideas, however. Enzo Maresca's side came out of the break much-improved and leveled the score in the 65th minute through Enzo Fernández. This time it was the turn of Chelsea's star man to make something happen and Palmer duly stepped up. The 23-year-old curled in an inviting cross which met the onrushing Fernandez. The Argentine timed his leap perfectly and glanced a header into the bottom corner of the Real Betis net. And Palmer was only just getting started. The side's creator-in-chief continued to probe, hovering around the Real Betis defense waiting for the opportune moment to strike. Isolated against 19-year-old Jesús Rodríguez, Palmer made his move and Chelsea took the lead. The 23-year-old chopped past his opponent before whipping in a right-footed cross in the direction of Chelsea forward Nicolas Jackson. The ball ricocheted off Jackson's chest and into the Betis goal to give Chelsea a crucial 2-1 lead. The irrepressibly gifted Palmer had singlehandedly turned the game on its head and suddenly Real Betis found itself on the backfoot. As Betis pressed for an equalizer, the Blues took advantage of the holes in the Spanish side's defense and grabbed another goal to double their advantage. Jadon Sancho picked up the ball on the left-hand side of the Betis box before cutting inside and curling a strike into the far corner of the goal. Chelsea then added another late goal on the break with Moisés Caicedo finishing off a lightning-fast counterattack. 'It's a great feeling, we knew the game was going to be tough and I think they showed that extremely in the first half,' Chelsea captain Reece James told the TNT broadcast after the game. 'But as the game went on, we grew into it and thankfully scored four goals in the second half.' Chelsea has already qualified for next season's Champions League and this success on the continent will give the young side belief ahead of next year's campaign. 'Coming into this competition, it was something we had to win ever since we got entered and next season we go again in the Champions League,' James added ahead of next season's sterner test.

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Business Wire

time16 minutes ago

  • Business Wire

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10 at 1:00 p.m. PT / 4:00 p.m. ET in Miami Beach, Florida. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store